Whitehawk Therapeutics (NASDAQ:WHWK) CEO David James Lennon Sells 63,945 Shares of Stock

Whitehawk Therapeutics, Inc. (NASDAQ:WHWK) CEO David James Lennon sold 63,945 shares of the stock in a transaction on Wednesday, April 8th. The stock was sold at an average price of $3.40, for a total value of $217,413.00. Following the completion of the sale, the chief executive officer owned 533,122 shares in the company, valued at $1,812,614.80. This trade represents a 10.71% decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

David James Lennon also recently made the following trade(s):

• On Tuesday, April 7th, David James Lennon sold 94,087 shares of Whitehawk Therapeutics stock. The stock was sold at an average price of $3.43, for a total value of $322,718.41.
• On Monday, April 6th, David James Lennon sold 102,395 shares of Whitehawk Therapeutics stock. The stock was sold at an average price of $3.51, for a total transaction of $359,406.45.
• On Thursday, April 2nd, David James Lennon sold 26,858 shares of Whitehawk Therapeutics stock. The stock was sold at an average price of $3.48, for a total transaction of $93,465.84.
• On Monday, March 2nd, David James Lennon sold 5,100 shares of Whitehawk Therapeutics stock. The stock was sold at an average price of $3.31, for a total transaction of $16,881.00.

Whitehawk Therapeutics Price Performance

WHWK stock opened at $3.41 on Thursday. Whitehawk Therapeutics, Inc. has a one year low of $1.39 and a one year high of $4.48. The stock has a market cap of $160.95 million, a PE ratio of 7.26 and a beta of 0.57. The firm has a 50 day simple moving average of $3.32 and a two-hundred day simple moving average of $2.69.

Whitehawk Therapeutics (NASDAQ:WHWK) last released its quarterly earnings results on Thursday, March 12th. The company reported ($0.34) EPS for the quarter, topping analysts’ consensus estimates of ($0.55) by $0.21.

Wall Street Analysts Forecast Growth

A number of equities analysts have commented on WHWK shares. Wall Street Zen raised shares of Whitehawk Therapeutics from a “sell” rating to a “hold” rating in a research note on Saturday, March 21st. JonesTrading started coverage on shares of Whitehawk Therapeutics in a research note on Monday, December 22nd. They issued a “buy” rating and a $7.00 price target for the company. Weiss Ratings reissued a “sell (d-)” rating on shares of Whitehawk Therapeutics in a research note on Friday, March 27th. Finally, Oppenheimer started coverage on shares of Whitehawk Therapeutics in a research note on Thursday, February 5th. They issued an “outperform” rating and a $6.00 price target for the company. Two equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the company has a consensus rating of “Hold” and an average price target of $6.50.

Institutional Investors Weigh In On Whitehawk Therapeutics

Hedge funds have recently made changes to their positions in the business. Quadrature Capital Ltd bought a new stake in shares of Whitehawk Therapeutics in the 4th quarter worth approximately $28,000. ABG Innovation Capital Partners III GP Ltd purchased a new stake in Whitehawk Therapeutics during the 3rd quarter valued at $51,000. Dimensional Fund Advisors LP purchased a new stake in Whitehawk Therapeutics during the 3rd quarter valued at $84,000. Marshall Wace LLP purchased a new stake in Whitehawk Therapeutics during the 4th quarter valued at $164,000. Finally, Jane Street Group LLC boosted its position in Whitehawk Therapeutics by 177.3% during the 4th quarter. Jane Street Group LLC now owns 69,931 shares of the company’s stock valued at $169,000 after buying an additional 44,716 shares during the period. 52.08% of the stock is currently owned by institutional investors.

About Whitehawk Therapeutics

Aadi Bioscience, Inc, a clinical-stage biopharmaceutical company, engages in developing and commercializing precision therapies for genetically defined cancers with alterations in mTOR pathway genes. Its lead drug candidate, FYARRO is a form of sirolimus bound to albumin. Aadi is evaluating FYARRO in cancers with known mTOR pathway activation, including tumor agnostic indications targeting specific genomic alterations that activate the mTOR pathway. The company was incorporated in 2007 and is headquartered in Pacific Palisades, California.